Intercell AG has signed an agreement with Cytos Biotechnology to acquire its monoclonal antibody discovery platform technology.
The technology facilitates anti-infective antibody identification to treat infectious diseases and is based on expression cloning of monoclonal antibodies from human B-cells.
Intercell will pay €15m to Cytos and own certain antibody assets as well as preclinical anti-infective antibody candidates discovered by Cytos.
Intercell will also employ the Cytos core research team, which developed the technology.
Antibodies are proteins that identify and bind to foreign substances so that scavenger cells can destroy them and flush them out of the body.